Peptides for Tropical Diseases Research

Tropical Diseases

About Tropical Diseases

Tropical diseases are diseases that are indigenous to subtropical or tropical regions and are less prevalent in temperate climates which are subject to seasonal changes. Whereas the term covers all communicable and non-communicable illnesses, genetic disorders, and conditions caused by nutritional deficiencies or environmental factors, we mostly understand tropical diseases to be of infectious nature. This is especially true, since rising migration and globalization have led to a faster spread of such diseases.

Besides socio-economic factors, high infection rates are largely attributed to the availability of many animal reservoirs for vector-borne transmission (e.g., bats, mosquitoes, flies), and a hot and moist climate accelerating replication of pathogens.

The WHO and other health programs established research institutions to study neglected infectious diseases, as they disproportionally affect low-income and marginalized regions in Africa, Asia, Central America, and South America, to provide monitoring-, diagnosis-, treatment-, and prevention tools to combat these diseases.

Our variety of peptide formats provide many necessary tools to monitor immune response of high-risk patients, epitope discovery, immunodominant antigen identification for development of vaccines, treatment solutions and diagnostics. Our peptides range from research-use-only to clinical formats that meet authority regulations.

List of common Tropical Diseases

The most commonly studied tropical diseases, for which we provide peptide tools, include:

Chagas Disease (Trypanosomiasis)

Crimean Congo Hemorhagic Fever

Dengue Fever

Ebola Fever

Lassa Fever

Malaria

Nipah Virus Disease

Tuberculosis

West Nile Fever

Yellow Fever

Zika Fever

JPT's Tropical Disease Peptides:

Filter products

B-cell Immunity

Cancer biomarker research

T-cell immunity

Antigen Peptides

PepMix Pan Select Peptide Pools

PepMix Peptide Pools

PepMix Peptide Pools Infections

PepMix Ultra Peptide Pools

PepStar Peptide Microarrays

African sleeping disease

Breast cancer

Chagas disease

Dengue fever

Diarrhea

Ebola

Ebola fever

Encephalitis

Fever

Hemorrhagic fever

Infection

Lassa fever

Leukemia

Liver failure

Melanoma

Meningitis

Microcephaly

Opportunistic infections

Respiratory infection

Sequence diversity

West nile fever

ZIKA fever

Zika virus disease

Andes Orthohantavirus

Crimean-Congo hemorrhagic fever virus (CCHFV)

Dengue virus

Ebola Virus (ZEBOV)

Ebola virus

Human

Lassa virus

M. tuberculosis

Nipah virus

Plasmodium

Trypanosoma cruzi

Trypanosoma vivax

West Nile Virus (WNV)

Yellow Fever Virus (YFV)

ZIKA virus (ZIKV)

6 kDa early secretory antigenic target

Alpha-crystallin

Antitoxin

Capsid protein

Circumsporozoite protein

Cruzipain

Diacylglycerol acyltransferase/mycolyltransferase

ESAT-6

ESAT-6-like protein

ESX-1 secretion-associated protein EspA

Energy-dependent translational throttle protein EttA

Envelope glycoprotein

Envelope protein

Envelopment polyprotein

Genome polyprotein

Glycoprotein

Heparin-binding hemagglutinin

Hypoxic response protein 1

Immunogenic protein MPT64

Low molecular weight T-cell antigen TB8.4

M protein

Nonstructural protein

Nucleoprotein

PPE family immunomodulator PPE68

PPE family protein

Phthiotriol/phenolphthiotriol dimycocerosates methyltransferase

Possible alanine rich dehydrogenase

Pre-glycoprotein polyprotein GP complex

Probable membrane protein Rv1733c

Probable protein

RING finger protein

Resuscitation-promoting factor

Selected proteins

Uncharacterized protein

No

Dengue virus Genome polyprotein 1608-1617, GTSGSPIADK

US$178.10

M. tuberculosis (strain ATCC 25177 / H37Ra) Ag85A 133-147, AGCQTYKWETFLTSE

M. tuberculosis (strain ATCC 25177 / H37Ra) Ag85A 166-174, SMAGSSAMI

M. tuberculosis (strain ATCC 25177 / H37Ra) Ag85A 166-180, SMAGSSAMILAAYHP

US$533.00

M. tuberculosis (strain ATCC 25177 / H37Ra) Ag85A 187-195, VYAGAMSGL

M. tuberculosis (strain ATCC 25177 / H37Ra) Ag85A 241-255, VANNTRLWVYCGNGT

M. tuberculosis (strain ATCC 25177 / H37Ra) Ag85A 304-318, THSWEYWGAQLNAMK

M. tuberculosis (strain ATCC 25177 / H37Ra) Ag85A 51-70, LQVPSPSMGRDIKVQFQSGG

M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 28-36, LLDEGKQSL

M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 82-90, AMASTEGNV

Cellular Immune Response

Antigen specific stimulation of T-cells

Immune monitoring of high-risk patients

Qualification of immunodominant antigens

Validating clinical T-cell assays

T-cell assays in

High-throughput T-cell epitope discovery

Monitoring of cellular immune response

Clinical trials

Humoral Immune Response

Immune monitoring of humoral responses

Profiling of specific samples or antibodies

Evaluation of co-infection

Detection of epitopes and epitope spreading

epitope discovery and epitope mapping

SPOT synthesis is a technique for custom synthesis of hundreds of membrane peptides in parallel

fast and economical

Clinical Peptides

Crimean-Congo Hemorrhagic Fever

About the Disease

This tick-borne viral disease causes severe symptoms two weeks after transmission, including fever, nausea, diarrhea, and a severe skin condition. More severely, CCHF may be associated by liver failure resulting in a very high fatality rate. As the name implies, the virus has been primarily found and is now endemic in Africa, Russia, the Balkans, the Middle East and India. According to the WHO, fatality rates range between 10-40%, making CCHF a priority disease for research and development.

Current Research

CCHF results from infection with CCHF virus, which is a member of the genus orthonairoviridae. This circular, negative sense stranded RNA virus recognizes seven genotypes that are dependent on location. However, CCHF virus is genetically quite diverse. The spread via ticks and migratory birds, as well as coinfections, contribute to the generation of such genetic variability in the same locations. Among other factors, this genetic spontaneity poses a challenge to vaccine development, and to date, none have been officially approved. Some supportive treatment options (ribavirin and immunoglobulin preparations) are available.

JPT's Peptide Tools to Study Crimean-Congo Hemorrhagic Fever

Dengue Fever

This mosquito-borne disease is caused by the Dengue Virus. Symptoms include fever, headache, vomiting and skin rash, and more severely hemorrhagic fever. Since the symptoms and regional occurrence overlaps, Dengue fever is often mistaken for Yellow Fever or Malaria.

Similar to the West Nile and Yellow Fever viruses, the single positive-stranded Dengue virus belongs to the genus of flavivirus, and occurs in the tropics and subtropics. 4 serotypes have so far been confirmed, with a potential 5th on the way.

Common immunogenic proteins that elicit an immune response are the envelope protein E, the membrane protein M, and NS2-5 proteins which include serine proteases, RNA helicases, RTPase/NTPase, methyltransferase, and other non-structural but co-factorial proteins. These NS proteins are considered potential targets for therapeutic intervention, but to date, no NS-inhibitors have been developed and released.

In addition, two Dengue vaccines have been approved: Qdenga (2022) and Dengvaxia (2016). The challenge is to develop a vaccine that covers all 4 (5) serotypes to be effective. Infection leads to the production of serotype-specific cross-reactive antibodies which do not neutralize other serotypes upon reinfection and may even enhance the rate of viral replication. Considering a 5th serotype might yet have to be confirmed, the development of an effective vaccine is crucial.

JPT’s Peptide Tools to Study Dengue Fever

Ebola

Ebolavirus Disease

Ebola virus disease or ‘Ebola fever’ is an often lethal hemorrhagic fever. Occasionally, Ebolaviruses cause disease outbreaks, mostly in African countries. These viruses infect humans and other primates and are likely to spread from bats to humans through contact with blood, body fluids, and tissues of infected animals.

Ebolaviruses belong to the family of Filoviridae. Four of the six known ebolavirus species cause disease in humans: Sudan ebolavirus, Bundibugyo ebolavirus, Tai Forest ebolavirus, and Zaire ebolavirus, with the latter having the highest mortality rate (83% on average). The 2014-2016 Ebola outbreaks in West Africa were caused by a Zaire ebolavirus strain and were considered among the most severe to date in terms of mortality. All ebolaviruses are in risk group 4 (RG4) of human and animal pathogens according to the WHO.

About Ebolavirus

Ebolaviruses are single-stranded RNA (ssRNA) viruses. Their genome codes for a number of proteins that are potentially relevant to the human immune response. These include, for example, a nucleoprotein (NP), a spike glycoprotein (GP), a polymerase cofactor, a transcription activator, and an RNA-dependent RNA polymerase.

If you are interested in viruses causing hemorrhagic fever, you may also be interested in the Crimean-Congo hemorrhagic fever virus (CCHFV), tools which will soon add to our catalog. It belongs to the genus of Orthonairoviruses and is tick-borne. It is also called the ‘Asian ebolavirus’, because the clinical picture in humans resembles ebolavirus disease and the underlying disease mechanisms appear very similar.

JPT's Peptide Tools to Study Ebola

Lassa Hemorrhagic Fever

Endemic in rodent populations in West Africa, human infection with the Lassa (mammarena-) virus occurs through exposure to urine- and feces-contaminated food. On more rare occasions, human-to-human transmission is also possible. Although 80% of people infected do not present any symptoms, the remaining 20% experience severe fever and less commonly bleeding from the mouth and gastrointestinal tract, resulting in an overall 1% case-fatality.

Belonging to the genus of mammarenaviruses the Lassa viruses are enveloped, single-stranded, bisegmented, ambisense RNA viruses, coding for four proteins: the small zing finger protein (Z), RNA polymerase, the nucleoprotein (NP) and surface glycoprotein (GP). Clinical diagnosis is difficult due to the wide range and non-specificity of presenting symptoms. There are currently no vaccines or treatments available, and reducing the infection rates relies solely on prevention and host controls.

JPT’s Peptide Tools to Study Lassa Hemorrhagic Fever

Malaria

Malaria is a tropical infectious and mosquito-borne disease caused by five types of Plasmodium parasites with P. falciparum and P. vivax being the deadliest. It is typically transmitted through mosquito saliva and symptoms occur within the following two weeks, including fever, fatigue, nausea, jaundice, seizures, and coma. These symptoms manifest particularly severe in children under the age of 5, and immunocompromised and pregnant people.

The above mentioned types of plasmodia are most prevalent in the African continent and other countries such as the South-East Asia and some areas of South and Central America, respectively. According to the World Malaria Report approximately 247 million infections and 619.000 deaths were reported in 2021 with cases being disproportionally prevalent in sub-Saharan Africa, such as Nigeria, Niger, the Democratic Republic of Congo, and Tanzania.

Malaria Research

Methods to reduce infections and mortality of malaria include bite prevention, early testing, chemoprophylaxis, and treatment. Considering parasite diversity, and the fact that these parasites display a high replication rate rendering resistance to treatment at a very fast pace, the task of developing prophylactic and immediate treatment plans is a complex process. In addition, infections, especially multiple infections, are unfortunately associated with a very slow process of acquired immunity, which in turn drives the demand for vaccine development.

Only recently the very first malaria vaccine RTS,S/AS01 became available and has so far immunized 1.5 million children in high-risk areas against P. falciparum (as of April 2023). This was soon followed by the even more effective vaccine R21/Matrix-M, which has been approved in Ghana for distribution and use in children under 5. Other vaccines using different technologies, and immunizing against different plasmodium types are currently in their trial-stages.

JPT’s Peptide Tools to Study Malaria

Nipah

Nipah virus disease – as the name implies – is caused by the Nipah virus. Although rare, human infection usually presents with fevers, coughs, headaches, breathing difficulties, and eventually inflammation of the brain with accompanying seizures and a very high likelihood of death, with the disease having a 50-75% risk of fatality. The disease occurs mainly in South-East Asian countries during the winter months. It is usually reported among farmers, and consumers of raw date palm sap and other fruits, or hospital workers, as the transmission occurs mainly through fruit bat and pig feces, and sometimes through fluids from person-to-person.

The WHO classifies Nipah virus as a priority disease, with multiple clinical trials for (mRNA or monoclonal antibody) vaccines on the way, including vector-, mRNA-, and monoclonal antibody-based platforms.

JPT’s Peptide Tools to Study Nipah Disease

Tuberculosis

About M. tuberculosis

Mycobacterium tuberculosis belongs to the family of Mycobacteriaceae and is the main cause for tuberculosis (TB). In most individuals M. tuberculosis does not cause acute clinical disease but remains a latent tuberculosis infection (LTBI). Nevertheless, TB is still a severe and potentially lethal infection of all times causing about 1.5 million deaths annually.

Unfortunately, TB vaccines provide incomplete protection, but appear to be able to prevent the most severe clinical courses. Improving TB vaccines is the focus of ongoing research studies worldwide. In addition a range of immunological TB diagnostics tests are available including both established clinical tests and experimental approaches.

Both the WHO and the United Nations defined global TB goals, to reduce infection rates and even to eradicate the epidemics by 2030, respectively.

One of these goals is the development of a new vaccine that overcomes the challenges of the current employed vaccine relying on M. bovis bacilli Calmette Guérin. More than a dozen TB vaccine candidates are under active clinical evaluation to prevent infection, disease, and recurrence. However, a reoccurring issue is the lack of reliable biomarkers to assess a vaccine’s efficacy. Furthermore, to monitor infections, affordable rapid-tests are being expanded. In 2021 the WHO issued a recommendation to improve access to testing and summarized innovations that are being investigated up to date.

We provide an extensive and continuously updated peptide catalog covering many antigens from Ag85 to ESAT-6 of secreted proteins allowing screening and monitoring humoral and cellular immune responses against these major TB antigens.

JPT's Peptide Tools to Study M. tuberculosis

West Nile Fever

West Nile Fever originated and was first described in Uganda in 1937. Although the majority of human infections are asymptomatic, 20% do in fact develop a fever, nausea, rash, and in 1% of cases encephalitis, meningitis, and seizures. Compared to humans however, West Nile Virus can cause severe disease and death in horses. It is transmitted by birds via mosquitos, and is subject to seasonal changes in climate.

West Nile Virus is another mosquito-borne virus of the of flavivirus genus, and its positive-sense single-stranded RNA is enveloped by an icosahedral capsid, membrane, and envelope proteins.. These structural proteins elicit immune responses, and are common targets for vaccine development and therapeutic intervention. Although vaccines are available for horses (an inactivated WNV vaccine (K-WN), a modified-live vaccine (CP-WN) and a live-chimera vaccine (WN-FV), none are yet available for humans, nor are there any treatment options.

JPT’s Peptide Tools to Study West Nile Fever

Yellow Fever

As expected, yellow fever is caused by the mosquito-borne yellow fever virus, which can be traced back to one of its main disease symptoms: yellow skin associated with liver damage. Other symptoms include, fever, nausea, muscle, head and abdominal pain, and more severely hemorrhagic fever.

Belonging to the flavivirus genus, this enveloped positive-sense single-stranded RNA virus is 40–50 nm wide and infects monocytes, macrophages, Schwann cells, and dendritic cells among others. According to the WHO, since 2023 13 countries and multiple regions in Central and South Africa report the disease as endemic.

Besides PCR blood testing and ELISA in late stage of Yellow Fever, early diagnosis renders itself difficult and symptoms often present themselves similar to other regionally common diseases. For preventative measures, a single-shot vaccination called YF-VAX with a live attenuated form of the virus derived from a 17D-204 strain is available and in increasing demand. However, there is no anti-viral treatment available to date. JPT’s Yellow Fever Peptides include a Single Antigen Peptides, a PepMix for cellular immune monitoring covering non-structural protein surfaces, a PepMix Pan Select addressing the virus’ sequence diversity, and PepStar Peptide microarrays for humoral immune monitoring purposes. Take your pick or consider our other customizable formats.

JPT’s Peptide Tools to Study Yellow Fever

Zika

About Zika Virus and other Flaviviruses

Zika virus (ZIKV) belongs to the flaviviruses such as dengue virus, West Nile virus, yellow fever virus, Saint Louis encephalitis virus and tick-borne encephalitis virus. Flaviviruses carry a positive-sense, single-stranded RNA and most flaviviruses are transmitted by the bite from an infected arthropod (mosquito or tick). We offer specific Zika virus peptides, Zika peptide pools and Zika peptide microarrays (ZIKV peptides, ZIKV peptide pools, ZIKV peptide microarrays).

Zika Virus:

Transmitted by the mosquitoes A. aegypti and A. albopictus

Was first isolated in 1947 from the Zika Forest of Uganda

From 2007 the virus spread across the Pacific Ocean to South America, leading to the Zika virus epidemic

Zika virus causes Zika fever or Zika virus disease

Usually shows no or only mild symptoms

Zika can also spread from a pregnant women to the fetuses

Causes microcephaly, severe brain malformations, and other birth defects in unborn children

References

References

CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infectionKelchtermans et al., Nature Immunology (2026)Product used: PepMix™ Sudan Ebolavirus (GP/Uganda-00)

Antibody-Based Antigen Delivery to Dendritic Cells as a Vaccination Strategy Against Ebola Virus DiseaseOlal et al., Journal of Infectious Diseases (2025) - PMID: 39852693Product used: Custom Peptide, Antigen Peptide, EBOV NP–derived peptide (NP44–52) YQVNNLEEI

Long-term cellular immunity of vaccines for Zaire Ebola Virus DiseasesWiedemann et al., Nature Communications (2024) - PMID: 39227399Product used: PepMix™ Zaire Ebola (GP/Mayinga-76)

Characterizing changes in transcriptome and kinome responses in testicular cells during infection by Ebola virusWebb et al., Viruses (2024) Product used: Custom PepStar

Early Sertoli cell gene expression regulates pathogenesis in response to Ebola virusWebb et al., Research Square (2023) Product used: Custom PepStar

Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge Lemmens et al., Vaccines (2023) Products used: PepMix™ Zaire Ebola (GP/Kikwit-95) & PepMix™ Yellow fever (NS4B)

A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccinesGomez et al., Vaccines (2022) - PMID: 36543794Products used: PepMix™ Zaire Ebola (GP/Mayinga-76)

Ebola Vaccine-induced Protection in Non-human Primates correlates with Antibody Specificity and Fc-mediated EffectsMeyer et al., SciTranslMed (2021) - PMID: 34261800

Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like ParticlesSchweneker et al., Journal of Virology (2017) - PMID: 28331098

Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent VaccineBlaney et al., PLOS Pathogens (2013) - PMID: 2373747

A vaccine targeting lung resident-memory CD4+ T cell phenotype protects against Mycobacterium tuberculosis in miceKo et al., NPJ Vaccines (2025) - PMID: 40695843Products used: PepMix™ M. tuberculosis (CFP-10), PepMix™ M. tuberculosis (ESAT-6)

Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assaysSchwarzlose-Schwarck et al., BMC Infectious Diseases (2025) - PMID: 39920589Products used: Peptrack Peptide Library, Custom PepMix, PepMix™ M. tuberculosis (ACR), PepMix™ M. tuberculosis (ESAT-6), PepMix™ M. tuberculosis (Rv1733c), PepMix™ M. tuberculosis (CFP-10), PepMix™ M. tuberculosis (TB10.4)

Efficacy and Immunogenicity of rKVAC85B in a BCG Prime-Boost Regimen Against H37Rv and HN878 Tuberculosis StrainsShin et al., Immunology & Microbiology (2024)Products used: PepMix™ M. tuberculosis (Ag85B)

A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCGDijkman et al., Vaccines (2023) - PMID: 37160970Products used: PepMix™ M. tuberculosis (ESAT-6), PepMix™ M. tuberculosis (MPT64), PepMix™ M. tuberculosis (PPE68), PepMix™ M. tuberculosis (EspA), custom PepMix™ (EspI, EspC, MPT70, MPT83)

Combined plasma cell-free DNA detection and IFNγ/TNF-α dual fluorospot assays for diagnosing active tuberculosis Kim et al., Research Square (2022)Products used: PepMix™ M. tuberculosis (ESAT-6), PepMix™ M. tuberculosis (CFP-10), PepMix™ M. tuberculosis (Ag85B)

Listeria-vectored multi-antigenic tuberculosis vaccine protects C57BL/6 and BALB/c mice and guinea pigs against Mycobacterium tuberculosis challengeJia et al., Communications Biology (2022)Products used: PepMix M. tuberculosis (Ag85B), M. tuberculosis (EspA), M. tuberculosis (EsxN), M. tuberculosis (TB8.4), M. tuberculosis (MPT64), custom PepMix (EsxH, EsxB, EsxA, ppe68),

Lentiviral vector-based T-cell vaccines against Zika and yellow fever virusesAuthié et al., Vaccine (2025) - PMID: 40753671Product used: PepMix™ ZIKV (NS1) Ultra

Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infection Martinot et al., Research Square (2024) Product used: PepMix™ ZIKV (E) Ultra, PepMix™ ZIKV (M) Ultra

Zika virus infection during pregnancy and vertical transmission: case reports and peptide-specic cellmediated immune responses Soudeyns et al., Research Sqaure (2023) Products used: PepMix™ HCMVA (pp65), PepMix™ ZIKV (NS1) Ultra, PepMix™ ZIKV (C) Ultra, PepMix™ ZIKV (E) Ultra

Rekombinowane cząstki wirusopodobne jako potencjalne antygeny szczepionkowe przeciwko wirusowi Zika Brzuska et al., Dissertation (2022)

Identification of Naturally Processed Zika Virus Peptides by Mass Spectrometry and Validation of T cell Recall Responses in Zika Convalescent Subjects Crooke et al., PLoS One (2021)

Generation of Zika Virus-Specific T Cells from Seropositive and Virus-Naïve Donors for Potential Use as an Autologous or "Off-the-Shelf" Immunotherapeutic Hanajiri et al, Cytotherapy (2019)

Vaccine Protection Against Zika Virus from Brazil Larocca et al., Nature (2016) PMID: 27355570

Protective Efficacy of Multiple Vaccine Platforms Against Zika Virus Challenge in Rhesus Monkeys Abbink et al., Science (2016) PMID: 27492477

Mapping the Sequence Space of ZIKA and Related Viruses: High-Content Peptide Libraries for Immune MonitoringVon Hoegen et al., Conference Poster (2016)

Identification of Naturally Processed Zika Virus Peptides by Mass Spectrometry and Validation of Memory T Cell Recall Responses in Zika Convalescent Subjects Crooke et al., PLoS One, (2021) Products used: PepMix™ ZIKV, PepMix™ Human (Actin)

mRNA Vaccine Protects against Zika VirusMedina-Magües et al., Vaccines, (2021)

Optimization of Zika DNA Vaccine by Delivery Systems Yun Ha Lee et al., Virology, (2021)

Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge Lemmens et al., BioRxiv (2023)Product used: PepMix™ Zaire Ebola (GP/Kikwit-95), PepMix™ Yellow fever (NS4B)

A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in miceKum et al., Emerging Microbes Infect. (2020) - PMID: 32116148

Protein Structure Shapes Immunodominance in the CD4 T Cell Response to Yellow Fever VaccinationKoblischke et al., Scientific Reports (2017) - PMID: 28827760

Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type responseBlom et al., Journal of Immunology (2013)

A Group of Infection-Enhancing and Focus Size-Reducing Monoclonal Antibodies Recognized an ‘a and c’ Strands Epitope in the pr Domain of Dengue Virus prMKeelapang et al., Virus Research (2024) Product used: PepSpot on Cellulose

Preexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human ChallengeLyke et al., Research Square (2023) Products used: Custom PepMix

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adultsFriberg et al., Vaccines (2022) - PMID: 36316335

A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infectionRonk et al., Nature Communications (2023) - PMID: 37699929Products used: Custom PepStar Peptide Microarrays

A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig modelKennedy et al., Vaccine (2019)

Identification of Broadly Neutralizing Monoclonal Antibodies Against Crimean-Congo Hemorrhagic Fever VirusZivcec et al., Antiviral Research (2017) - PMID: 28842265

A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah diseasePastor et al., Cell Reports Medicine (2024) - PMID: 38471503Products used: PepMix™ Nipah Virus (Nucleoprotein N), PepMix™ Nipah virus (Glycoprotein G), PepMix™ Nipah Virus (Fusion Glycoprotein F0) and Custom PepMix™

Dendritic cell-specific function of deubiquitinating enzyme OTUD7b in experimental cerebral malariaHarit., Dissertation (2024)Product used: Custom Peptides (for GAP-50 peptide (SQLLNAKYL))

Application Notes

Application Note The Challenge of Antigen Sequence Diversity: Solutions with ULTRA-Peptide LibrariesU. Reimer et al., Application Note (2016)

A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune ResponsesN. Pawlowski, J. Jansong, J. Zerweck, U. Reimer, Application Note (2013)

Qualification and Use of Peptide Libraries for Clinical Trial ImmunomonitoringJ. H. Cox & P. Hayes, Application Note (2013)